Ykrita Life Sciences is a technology company.
Ykrita Life Sciences has raised $1.0M across 1 funding round.
Ykrita Life Sciences has raised $1.0M in total across 1 funding round.
Ykrita Life Sciences has raised $1.0M in total across 1 funding round.
Ykrita Life Sciences's investors include Venture Catalysts | India's First Integrated Incubator.
Ykrita Life Sciences is a biotechnology startup developing the EBDLR v2.0, an extracorporeal bioengineered dual-cell liver regeneration system that supports liver function, purifies blood, and enables native liver regeneration in patients with acute liver failure (ALF), serving as an alternative to costly and scarce liver transplants.[1][2][4] The lightweight, portable, and budget-friendly device targets patients in India and beyond, addressing ALF—a life-threatening condition with 40-50% mortality caused by drug toxicity, hepatitis, or poisoning—primarily serving clinicians and underserved populations lacking transplant access.[1][2][4] Founded in 2020 in Bengaluru, India, the company has secured USD 1.2 million in seed funding led by Venture Catalysts, filed patents in India, PCT, and USPTO, and shown promising preclinical results, positioning it for growth in the USD 60 billion global liver disorder market.[1][2][4]
Ykrita Life Sciences was founded in 2020 in Bengaluru, India, by Dr. Mahesh Gopasetty, a clinician driving the clinical and biological sciences efforts, alongside a team of interdisciplinary scientists, engineers, and clinicians.[1][3][4] The idea emerged from the critical need to treat ALF, where liver transplants are the only option but limited by cost and organ shortages; incubated initially at the Indian Institute of Science (IISc), it transitioned to C-CAMP, India's leading bio-incubation facility, to accelerate research and product development.[2] Early traction included promising preclinical studies demonstrating the device's ability to rescue ALF subjects, leading to a USD 1.2 million seed round in 2023 led by Venture Catalysts, which validated its potential to democratize access for millions in India.[1][2]
Ykrita rides the wave of bioengineered medical devices and regenerative medicine, targeting ALF amid rising demand for transplant alternatives in emerging markets where hepatitis and toxicity drive high incidence rates.[1][2][4] Timing aligns with global liver disorder market growth to USD 60 billion, fueled by aging populations, better diagnostics, and India's biotech boom via incubators like C-CAMP; market forces like organ shortages (limiting transplants) and funding for deep-tech health startups favor its portable, scalable model.[1][2] It influences the ecosystem by pioneering affordable extracorporeal therapies, potentially disrupting high-cost interventions and inspiring similar devices for other organ failures in low-resource settings.[1][2]
Ykrita is poised for clinical trials and regulatory approvals next, leveraging seed funding and patents to scale EBDLR v2.0 toward commercialization, potentially entering markets by 2027-2028.[1][2][4] Trends like AI-driven bioengineering, personalized medicine, and India’s push for Atmanirbhar biotech will shape its path, expanding to chronic liver conditions or global partnerships. Its influence could grow by reducing ALF mortality in underserved regions, evolving from a niche startup to a leader in accessible organ-support tech—ultimately saving lives where transplants fall short.[1][2]
Ykrita Life Sciences has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $1.0M Seed | Venture Catalysts | India's First Integrated Incubator |